Trademark Registration in China

By Ubbat Ocak in 2019 Posted May 5, 2019

Trademark registration of Sutrips in China

MUB Medical Successfully Secures Trademark Registration for Sutrips in China

We are delighted to announce a major accomplishment for MUB Medical Solutions. The trademark registration process for our groundbreaking wound closure solution, Sutrips, has been successfully finalized in the expansive Chinese market.

The completion of trademark registration in China bolsters our commitment to safeguarding our Intellectual Property rights in crucial strategic markets. China’s significance in the healthcare industry makes it an essential market for us, and this registration fortifies our position in protecting the unique brand and cutting-edge technologies of Sutrips.

“Our achievement in securing trademark registration in China is a significant leap forward for MUB Medical Solutions,” expresses Ubbat Ocak, Founder of MUB Medical Solutions. “China offers immense opportunities for Sutrips, and we are resolute in providing the highest level of IP protection to ensure the exclusivity and integrity of our brand.”

As part of our continuous efforts, we are actively pursuing trademark registrations in other identified strategic markets for Sutrips. By establishing a strong global presence, we aim to collaborate with esteemed business partners who are influential leaders in the field of wound closure.

“We are steadfast in delivering exceptional IP protection to our valued business partners, who are instrumental players in the wound closure industry,” emphasizes Yasar Shaikh, CEO of MUB Medical Solutions. “By securing trademark registrations in key markets, we demonstrate our unwavering dedication to safeguarding our innovations and offering a competitive advantage to our partners.”

The successful completion of trademark registration in China signifies a significant milestone that positions MUB Medical Solutions for further growth and success. We will persist in pursuing additional trademark registrations globally, expanding our reach and creating remarkable opportunities for collaboration and market expansion.

Stay connected with us through our website and social media channels as we continue to make remarkable strides in the realm of wound closure. Our unwavering commitment to innovation and providing top-tier IP protection remains at the forefront of our mission to serve our esteemed business partners.

Trademark Registration in UK

By Ubbat Ocak in 2019 Posted April 5, 2019

Trademark Registration in the United Kingdom

We are thrilled to announce that MUB Medical Solutions has achieved a significant milestone in our journey to protect and strengthen our Intellectual Property rights. We have successfully completed the trademark registration process for Sutrips in the United Kingdom, one of our key strategic markets.

This trademark registration is a crucial step towards safeguarding our brand and innovative medical solutions. It provides us with exclusive rights to the Sutrips name and logo, offering enhanced legal protection against unauthorized use or infringement. By securing our intellectual property, we ensure that our partners and customers can trust in the authenticity and quality of our products.

“We are delighted to have completed the trademark registration for Sutrips in the United Kingdom,” says Ubbat Ocak, Founder of MUB Medical Solutions. “This achievement reinforces our commitment to building a strong global presence and protecting our valuable intellectual property. It empowers us to actively prevent counterfeiting and maintain our competitive edge in the market.”

As we continue to expand our reach and serve healthcare professionals worldwide, we recognize the importance of intellectual property protection in key strategic markets. Our team is dedicated to pursuing trademark registration in additional countries that have been identified as vital markets for Sutrips. By proactively securing our IP rights, we create a solid foundation for future growth and ensure that our innovations remain uniquely positioned in the market.

“Our mission is not only to revolutionize wound closure but also to provide our business partners with the highest level of IP protection,” says Yasar Shaikh, CEO of MUB Medical Solutions. “The completion of the trademark registration in the United Kingdom is a significant step towards achieving that goal. We are committed to delivering the best possible IP protection for our partners and customers, enabling them to confidently collaborate with us and leverage the benefits of our innovative solutions.”

MUB Medical Solutions is proud to have achieved this milestone in our intellectual property journey. We remain steadfast in our dedication to delivering cutting-edge medical devices and ensuring that our partners and customers receive the utmost protection and value from their association with us.

Stay tuned as we continue to make strides in advancing wound closure technology and expanding our IP protection worldwide. Follow us on our social media platforms and website to stay informed about our latest updates and exciting developments.

Explore EU Design Registration.

EU Design Registration

By Ubbat Ocak in 2019 Posted February 4, 2019

Design Registration of Sutrips in the EU

MUB Medical is thrilled to announce that the design of Sutrips has been successfully granted protection in the European Union (EU). This design protection further bolsters our strong intellectual property (IP) rights surrounding Sutrips, which is already patented in the EU.

The design protection for Sutrips in the EU is a significant achievement for our company. It ensures that the unique and innovative design of Sutrips is legally safeguarded, providing us with exclusive rights to its visual appearance. This protection reinforces our commitment to delivering cutting-edge medical solutions while safeguarding our intellectual assets.

With Sutrips, we bring numerous advantages to the field of wound closure. Sutrips is a revolutionary all-in-one suture tool that simplifies the wound closure process. Its ergonomic design and user-friendly features enable medical professionals to efficiently and effectively close wounds. By combining all the necessary components of a traditional stitching kit into a single device, Sutrips streamlines procedures, saves time, and enhances patient care.

In addition to its design and functionality, Sutrips offers exceptional versatility. It is suitable for various wound types, sizes, and locations, making it a valuable tool for emergency rooms, surgical procedures, and everyday wound care. With Sutrips, healthcare professionals can achieve precise wound closure, leading to improved outcomes and patient satisfaction.

The combination of patent protection and design protection in the EU for Sutrips strengthens our position as a leader in the field of wound closure innovation. We remain committed to advancing medical solutions that make a meaningful difference in healthcare, and we are proud to have Sutrips at the forefront of this mission.

For more information about Sutrips and our innovative products, please visit our website or contact our team. Together, we can revolutionize wound closure and improve patient care worldwide.

Explore Geneticum and Proventia.

Geneticum and Proventia

By Ubbat Ocak in 2019 Posted January 5, 2019

MUB Medical Granted Funding & Joins Proventia Incubator Program to Drive Growth and Innovation!

We are delighted to announce that MUB Medical Solutions has successfully secured funding from two esteemed organizations, Stiftelsen Geneticum and Proventia. This financial support marks a significant milestone in our journey to bring Sutrips to the forefront of the wound closure industry.

The funding received from Stiftelsen Geneticum and Proventia will play a vital role in our mission to advance the regulatory pathway for Sutrips. With this financial backing, we will initiate a comprehensive study to navigate the regulatory landscape and ensure compliance with industry standards and requirements. This important step brings us closer to achieving the necessary certifications and approvals needed to bring Sutrips to market.

“We are incredibly grateful for the generous funding provided by Stiftelsen Geneticum and Proventia,” says Ubbat Ocak, Founder of MUB Medical Solutions. “Their support is a testament to their belief in our vision and the potential impact of Sutrips in revolutionizing wound closure. With this funding, we can accelerate our efforts to navigate the regulatory pathway and ensure that Sutrips meets all necessary regulatory standards.”

By securing these funds, we can dedicate resources to conduct in-depth research, collaborate with regulatory experts, and streamline the process of obtaining regulatory approvals. This study will provide us with valuable insights and enable us to develop a robust regulatory strategy that ensures the safety, efficacy, and compliance of Sutrips.

Yasar Shaikh, CEO of MUB Medical Solutions, emphasizes the significance of this funding in propelling our mission forward. “The funding from Stiftelsen Geneticum and Proventia is a game-changer for us. It enables us to take concrete steps towards fulfilling regulatory requirements and ultimately bringing Sutrips to the hands of healthcare professionals and patients who can benefit from its innovative wound closure capabilities.”

We extend our deepest gratitude to Stiftelsen Geneticum and Proventia for their trust and support in our vision. Their funding enables us to forge ahead in our mission to improve wound closure practices and provide healthcare professionals with a revolutionary solution.

Stay tuned for more updates as we progress through the regulatory pathway and work towards making Sutrips a reality. Follow us on our social media platforms and website to stay informed about our latest developments and milestones.

Explore Klosteroya Fondet and Proventia.

Klosterøya Fondet and Proventia

By Ubbat Ocak in 2018 Posted December 5, 2018

MUB Medical Receives Development Loan and Joins Proventia Preincubation Program

MUB Medical is thrilled to announce two major milestones that will propel us forward in our mission to transform the wound closure industry. We have been offered a development loan by Klosterøya Fondet, a testament to our potential for growth and innovation. Additionally, we are excited to share that we have joined the renowned Proventia preincubation program, further strengthening our position in the entrepreneurial ecosystem.

Founder Ubbat Ocak expresses his enthusiasm, stating, “The development loan from Klosterøya Fondet is a significant milestone for MUB Medical. It will provide us with the financial resources needed to accelerate the development of our revolutionary wound closure solutions. We are grateful for the support and trust shown by Klosterøya Fondet in our vision and look forward to delivering innovative products that will make a positive impact.”

CEO Yasar Shaikh adds, “Joining the Proventia preincubation program marks a crucial step in our growth journey. Incubation has proven to be an effective method for nurturing and realizing new business ideas, and we are excited to collaborate with Proventia’s experienced team. Their support in terms of services, infrastructure, networks, and investor connections will be instrumental in shaping our path to success.”

Proventia, established in 2013, is renowned for its dedication to helping entrepreneurs and visionaries commercialize unique business ideas with regional potential. Their focus on supporting and guiding founders aligns perfectly with MUB Medical’s goals. Through this program, we will have access to valuable resources, expertise, and networks that will enable us to refine our business model and maximize our potential for success.

“Proventia’s commitment to developing sound business ideas into profitable ventures resonates with our vision at MUB Medical,” states Yasar Shaikh. “We appreciate their dedication to our success and their role in fostering sustainable growth in the region. Together, we will navigate the entrepreneurial journey, with a shared goal of realizing dreams and creating innovative solutions.”

As we embark on this exciting chapter, we extend our gratitude to Klosterøya Fondet and Proventia for their belief in our vision and their support in our journey to revolutionize the wound closure industry. These partnerships will strengthen our ability to invest in research, development, and analyzing the patent landscape, further solidifying our position as a key player in the healthcare sector.

Stay connected with MUB Medical on our LinkedIn page for updates on our progress, new developments, and exciting milestones. We are committed to advancing wound closure solutions and driving positive change in the industry.

Funding From Innovation Norway

By Ubbat Ocak in 2018 Posted April 29, 2018

MUB Medical Secures Funding from Innovation Norway

MUB Medical, a pioneering medical device company, is thrilled to announce that it has been granted funding from Innovation Norway, Commercialization Phase 1, the Norwegian Government’s leading catalyst for innovation and enterprise development. This funding marks a significant milestone in MUB Medical’s journey towards revolutionizing wound closure solutions with its groundbreaking product, Sutrips.

Innovation Norway plays a vital role in supporting and promoting the growth of Norwegian businesses by fostering innovation and enhancing their competitive advantage. With their comprehensive range of programs and services, Innovation Norway empowers entrepreneurs, facilitates the development of high-growth enterprises, and fosters collaborative innovation ecosystems.

The funding received from Innovation Norway will provide MUB Medical with valuable resources to further invest in the development of Sutrips. This includes conducting in-depth analysis of the patent landscape to ensure the product’s uniqueness and competitive edge. By leveraging this funding, MUB Medical aims to accelerate its research and development efforts, enhancing the functionality and effectiveness of Sutrips to meet the evolving needs of healthcare professionals.

“We are delighted to receive this funding support from Innovation Norway,” said Ubbat Ocak, Founder of MUB Medical. “This investment will enable us to strengthen our commitment to innovation and propel our mission of revolutionizing wound closure solutions. With the backing of Innovation Norway, we are confident in our ability to deliver cutting-edge products that improve patient outcomes and transform the healthcare industry.”

“MUB Medical is dedicated to developing advanced medical devices that simplify and optimize wound closure procedures, ultimately improving the quality of care for patients” said Yasar Shaikh, CEO of MUB Medical. “The funding received from Innovation Norway will not only fuel the development of Sutrips but also bolster MUB Medical’s position as an innovator in the field of wound closure technology”.

About MUB Medical:

MUB Medical is a progressive medical device company focused on revolutionizing wound closure solutions. With a commitment to innovation and simplicity, MUB Medical aims to empower healthcare professionals with advanced tools that enhance patient care and outcomes. Their flagship product, Sutrips, represents a paradigm shift in wound closure, offering efficient, reliable, and user-friendly solutions for medical practitioners.

For more information about MUB Medical and its innovative products, please visit www.mubmedical.com and follow LinkedIn page for exciting updates www.linkedin.com/company/mub-medical-solutions-as/

About Innovation Norway:

Innovation Norway is the Norwegian Government’s foremost instrument for innovation and development of Norwegian enterprises and industry. Through its comprehensive range of programs and services, Innovation Norway supports businesses in developing their competitive advantage and fostering innovation across various sectors of the Norwegian economy. By stimulating profitable business development and encouraging collaboration, Innovation Norway plays a vital role in driving economic growth and sustainable development in Norway.